December 3, 2022
Florey Institute and Global Kinetics Announce Results from Randomized Clinical Trial of the Personal KinetiGraph® (PKG®) in Persons with Parkinson’s Disease

Study demonstrates the use of a wearable device in treatment of Parkinson’s disease resulted in significant improvement in patient outcomes compared to standard of care management.

The Florey Institute and Global Kinetics Pty Ltd. today announced that data from a new clinical study of the FDA-cleared wearable Personal KinetiGraph® (PKG®) has been published in the Nature Partners Journal – Parkinson’s Disease (npj – Parkinson’s Disease).

The study entitled “A controlled trial of objective measurement to guide therapy improves outcomes in Parkinson’s disease” adds to the body of evidence showing the advantages of using a wearable, continuous objective measurement system in the monitoring and management of motor symptoms affecting people with Parkinson’s disease (PD).

Read the press release


Share This Post